Chinese medicine formulation for curing pulmonary fibrosis

Abstract

The invention discloses a Chinese medicine formulation for curing pulmonary fibrosis. it is prepared from, by weight, 10 g codonopsis pilosula, 10 g wolfiporia cocos, 20 g atractylodes macrocephala, 15 g astragalus mongholicus, 10 g angelica sinensis, 10 g fritillaria thunbergii, 6 g sophoraflavescens, 3 g panax notoginseng powder, 13 g earthworm, 10 g turtle shell (decocted earlier), 15 g cornus officinalis, 30 g china dodder, 10 g acorus tatarinowii, 10 g radix curcumae. The preparation and using methods of the Chinese medicine composition of the invention are: decocting in water for an oral dose, one dose a day, taking twice a day separately, seven days as a course of treatment, generally taking 1-2 courses.

Description

technical field [0001] The invention belongs to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine formula for treating pulmonary interstitial fibrosis. Background technique [0002] Pulmonary interstitial fibrosis is a pulmonary interstitial lesion caused by different etiologies or unknown causes. Its pathological features are early alveolar structural destruction and diffuse alveolitis, followed by excessive deposition of extracellular matrix, and gradually develops into diffuse pulmonary fibrosis. Interstitial fibrosis, resulting in pulmonary dysfunction, most patients died of progressive respiratory failure. According to data, unexplained idiopathic pulmonary fibrosis (Idiopathicpulmonary Fibrosis, IPF) accounts for about 60-65% of pulmonary interstitial diseases, is the most common pulmonary interstitial disease, and its 5-year survival rate is lower than 50%, and the 10-year survival rate is about 30%. At present, the incidenc...

AI Technical Summary

Problems solved by technology

[0003] At present, the clinical treatment of pulmonary interstitial fibrosis mainly adopts hormones, immunosuppressants, cytotoxic drugs (such as thiazolin, cyclophosphamide) and anti-fibrotic agents (such as colchicine, D-cyanine, etc.). Mycamine) alone or in combination, but no matter which treatment method lacks effectiveness and has relatively large side effects

[0004] In addition, some new ideas and treatment methods have emerged for the treatment of pulmonary interstitial fibrosis, such as the use of cytokine inhibitors, anti-adhesion molecule antibodies, anti-C-C chemokines, antioxidants, antagonism of extracellular matrix deposition, Anti-protease, etc., but many of the above methods for treating pulmonary interstitial fibrosis are still in the stage of experimental research or clinical research

So far, there is no drug that can change or reverse the inflammatory process and fibrosis process of pulmonary interstitial fibrosis.